| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.22 | 8e-05 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.0002 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |